Annual Cash & Cash Equivalents
$34.59 M
+$1.67 M+5.08%
31 December 2023
Summary:
Inozyme Pharma annual cash & cash equivalents is currently $34.59 million, with the most recent change of +$1.67 million (+5.08%) on 31 December 2023. During the last 3 years, it has risen by +$6.55 million (+23.35%). INZY annual cash & cash equivalents is now -3.83% below its all-time high of $35.97 million, reached on 31 December 2018.INZY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$24.57 M
+$9.34 M+61.33%
30 September 2024
Summary:
Inozyme Pharma quarterly cash and cash equivalents is currently $24.57 million, with the most recent change of +$9.34 million (+61.33%) on 30 September 2024. Over the past year, it has dropped by -$22.32 million (-47.60%). INZY quarterly cash and cash equivalents is now -60.76% below its all-time high of $62.62 million, reached on 30 June 2022.INZY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INZY Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.1% | -47.6% |
| 3 y3 years | +23.4% | -9.8% |
| 5 y5 years | -3.8% | - |
INZY Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +48.3% | -60.8% | +61.3% |
| 5 y | 5 years | -3.8% | +48.3% | -60.8% | +61.3% |
| alltime | all time | -3.8% | +48.3% | -60.8% | +61.3% |
Inozyme Pharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $24.57 M(+61.3%) |
| June 2024 | - | $15.23 M(-26.1%) |
| Mar 2024 | - | $20.62 M(-40.4%) |
| Dec 2023 | $34.59 M(+5.1%) | $34.59 M(-26.2%) |
| Sept 2023 | - | $46.90 M(+14.8%) |
| June 2023 | - | $40.84 M(-16.7%) |
| Mar 2023 | - | $49.02 M(+48.9%) |
| Dec 2022 | $32.91 M | $32.91 M(-25.3%) |
| Sept 2022 | - | $44.04 M(-29.7%) |
| June 2022 | - | $62.62 M(+96.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $31.94 M(+37.0%) |
| Dec 2021 | $23.32 M(-16.8%) | $23.32 M(-14.4%) |
| Sept 2021 | - | $27.23 M(+3.8%) |
| June 2021 | - | $26.24 M(+59.2%) |
| Mar 2021 | - | $16.49 M(-41.2%) |
| Dec 2020 | $28.04 M(-11.3%) | $28.04 M(-53.2%) |
| Sept 2020 | - | $59.86 M(+17.7%) |
| June 2020 | - | $50.86 M(-8.6%) |
| Mar 2020 | - | $55.64 M(+76.0%) |
| Dec 2019 | $31.61 M(-12.1%) | $31.61 M |
| Dec 2018 | $35.97 M | - |
FAQ
- What is Inozyme Pharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Inozyme Pharma?
- What is Inozyme Pharma annual cash & cash equivalents year-on-year change?
- What is Inozyme Pharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Inozyme Pharma?
- What is Inozyme Pharma quarterly cash and cash equivalents year-on-year change?
What is Inozyme Pharma annual cash & cash equivalents?
The current annual cash & cash equivalents of INZY is $34.59 M
What is the all time high annual cash & cash equivalents for Inozyme Pharma?
Inozyme Pharma all-time high annual cash & cash equivalents is $35.97 M
What is Inozyme Pharma annual cash & cash equivalents year-on-year change?
Over the past year, INZY annual cash & cash equivalents has changed by +$1.67 M (+5.08%)
What is Inozyme Pharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of INZY is $24.57 M
What is the all time high quarterly cash and cash equivalents for Inozyme Pharma?
Inozyme Pharma all-time high quarterly cash and cash equivalents is $62.62 M
What is Inozyme Pharma quarterly cash and cash equivalents year-on-year change?
Over the past year, INZY quarterly cash and cash equivalents has changed by -$22.32 M (-47.60%)